Ventricular hyperinnervation in a mouse model of catecholaminergic polymorphic ventricular tachycardia

M O'reilly,T De Waal,S Casini,C A Remme

DOI: https://doi.org/10.1093/cvr/cvae088.098

IF: 13.081

2024-05-31

Cardiovascular Research

Abstract:Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): European Society of Cardiology Basic Research Fellowship. Dutch Heart Foundation Dekker Grant Background Inherited arrhythmia syndromes are a leading cause of sudden cardiac death in young and otherwise healthy patients. They are often caused by mutations in genes that encode ion channels or transporters, leading to conditions such as Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). CPVT is caused by mutations in RYR2 (encoding ryanodine receptor 2, RyR2). In arrhythmia research, investigation into the effects of these mutations have exclusively been performed in cardiac cells. However, RyR2 is also present in neuronal tissue, including intracardiac neurons [1] (which modulate cardiac function). Moreover, patients often present with clinical signs of autonomic nervous system (ANS) dysfunction, and treatment strategies frequently target the ANS. Aim Our novel research line aims to investigate the neuronal phenotype induced by RyR2 mutations, using a CPVT mouse model to assess functional alterations as well as broader autonomic remodelling. Results Using immunocytochemistry, we reveal for the first time that RyR2 is also expressed in mouse stellate ganglia (crucial autonomic modulators of cardiac function). Through analysis of published RNA sequencing datasets, we find that RYR2 is more abundantly expressed in both stellate ganglion and intracardiac neurons than characteristic neuronal markers such as CHAT, SYN1 and SCN8A [2,3]. Functional patch clamp investigation of isolated stellate ganglion neurons have revealed two distinct populations based on their patterns of action potential (AP) firing, identifying both phasic-firing and tonic-firing type neurons. Investigation of an established CPVT mouse model (RyR2-R2474S) has thus far not revealed any differences in the AP firing frequency of isolated stellate ganglion neurons during sustained depolarising stimuli of various amplitudes. Assessment of calcium homeostasis and neurotransmitter release is currently ongoing. We have furthermore investigated broader autonomic remodelling using immunohistochemistry in mouse heart cryosections. Neuronal innervation density was assessed by staining 10 μm sections of mid-ventricular myocardium for the sympathetic neuron marker tyrosine hydroxylase (TH). Quantification of the TH-positive area revealed a significant increase in the percentage of sympathetic neuronal innervation in ventricular tissue of CPVT mice (5.7% wild-type vs 7.2% RyR2-R2474S, p=0.0253, N=6). Conclusions The neurons that modulate heart function (stellate ganglion and intracardiac neurons) abundantly express RyR2. The RyR2-R2474S mutation leads to significant sympathetic hyper-innervation of ventricular myocardium, which may have important consequences for neurotransmitter release and hence cardiac (electrical) function and arrhythmogenesis.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The problems that this paper attempts to solve are: **To explore the manifestations of RyR2 gene mutations in neurons and their impacts on the cardiac autonomic nervous system (ANS), especially in the catecholaminergic polymorphic ventricular tachycardia (CPVT) mouse model, whether RyR2 mutations will lead to myocardial sympathetic hyperinnervation, thus affecting cardiac function and the occurrence of arrhythmia.**

Specifically:

1. **Background problems**:
- Inherited arrhythmia syndromes are one of the main causes of sudden cardiac death in young and otherwise healthy patients.
- CPVT is caused by mutations in the RYR2 gene (encoding ryanodine receptor 2, RyR2).
- Previous studies have mainly focused on the effects of these mutations in cardiac cells, but RyR2 is also expressed in neural tissues, including neurons in the heart, and these neurons regulate cardiac function.
- Patients often show clinical symptoms of autonomic nervous system (ANS) dysfunction, and treatment strategies are often aimed at the ANS.

2. **Research objectives**:
- To explore the neural phenotypes in the mouse model caused by RyR2 mutations, and to evaluate functional changes and more extensive autonomic nerve remodeling.
- To pay special attention to the expression of RyR2 in stellate ganglia and neurons in the heart and its impact on cardiac function.

3. **Research results**:
- It was first discovered by immunocytochemistry that RyR2 is expressed in the stellate ganglia of mice.
- RNA - sequencing data analysis shows that the expression levels of RYR2 in stellate ganglia and neurons in the heart are higher than some typical neuronal markers (such as CHAT, SYN1 and SCN8A).
- Functional patch - clamp experiments revealed two different types of stellate ganglion neurons (phasic - firing and tonic - firing), but no significant difference in the action potential (AP) firing frequency during stimulation was found in the CPVT mouse model (RyR2 - R2474S).
- Immunohistochemistry results show that the density of sympathetic nerve fibers in the ventricular tissue of CPVT mice increased significantly (TH - positive area: wild - type 5.7% vs RyR2 - R2474S 7.2%, p = 0.0253, N = 6).

4. **Conclusions**:
- Neurons that regulate cardiac function (such as stellate ganglia and neurons in the heart) highly express RyR2.
- The RyR2 - R2474S mutation leads to sympathetic hyperinnervation of the ventricular myocardium, which may have an important impact on neurotransmitter release, and further affect cardiac (electrical) function and the occurrence of arrhythmia.

Through the above research, the paper aims to reveal that RyR2 mutations not only affect cardiac cells, but may also further affect cardiac health by changing the structure and function of the autonomic nervous system.